STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers.

CRISPR-Cas Systems Cell Cycle Proteins / deficiency Cell Line, Tumor Chromosomal Proteins, Non-Histone / genetics Disease Susceptibility Gene Silencing Gene Targeting Genome-Wide Association Study Humans Models, Molecular Neoplasms / genetics Nuclear Proteins / chemistry Protein Binding Proteolysis Structure-Activity Relationship Synthetic Lethal Mutations Cohesins

Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
07 2020
Historique:
received: 31 03 2020
revised: 13 05 2020
accepted: 14 05 2020
entrez: 30 5 2020
pubmed: 30 5 2020
medline: 8 7 2021
Statut: epublish

Résumé

The cohesin subunit

Identifiants

DOI: 10.26508/lsa.202000725 PMID: 32467316 PMC: PMC7266993
pubmed: 32467316
pii: 3/7/e202000725
doi: 10.26508/lsa.202000725
pmc: PMC7266993
pii:
doi:

Substances chimiques

Cell Cycle Proteins 0
Chromosomal Proteins, Non-Histone 0
Nuclear Proteins 0
STAG1 protein, human 0
STAG2 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106169/ZZ14/Z
Pays : United Kingdom

Informations de copyright

© 2020 van der Lelij et al.

Références

Science. 2011 Aug 19;333(6045):1039-43
pubmed: 21852505
Curr Opin Cell Biol. 2019 Jun;58:8-14
pubmed: 30544080
Elife. 2017 Jul 10;6:
pubmed: 28691904
Science. 2015 Nov 27;350(6264):1096-101
pubmed: 26472758
Yeast. 2013 Sep;30(9):341-51
pubmed: 23836714
FEBS Lett. 2014 Oct 16;588(20):3692-702
pubmed: 25171859
Blood. 2014 Sep 11;124(11):1790-8
pubmed: 25006131
Nat Genet. 2013 Oct;45(10):1232-7
pubmed: 23955599
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
Mol Cell. 2002 Apr;9(4):773-88
pubmed: 11983169
Curr Opin Genet Dev. 2019 Feb;54:41-47
pubmed: 30951975
Science. 2018 May 18;360(6390):800-805
pubmed: 29622725
Nat Methods. 2013 Oct;10(10):965-71
pubmed: 24161985
Nature. 2015 Sep 24;525(7570):543-547
pubmed: 26367798
Nat Methods. 2020 Jul;17(7):708-716
pubmed: 32514112
Nat Genet. 2013 Nov;45(11):1293-9
pubmed: 24056718
Nat Genet. 2015 Feb;47(2):106-14
pubmed: 25501392
Nat Commun. 2019 Apr 11;10(1):1686
pubmed: 30975996
Curr Biol. 2011 Jan 11;21(1):12-24
pubmed: 21185190
Biochim Biophys Acta. 2016 Aug;1866(1):1-11
pubmed: 27207471
Nature. 2014 Jan 16;505(7483):367-71
pubmed: 24291789
J Exp Med. 2015 Oct 19;212(11):1819-32
pubmed: 26438361
Genes Dev. 1999 Feb 1;13(3):320-33
pubmed: 9990856
Nat Commun. 2019 Dec 20;10(1):5817
pubmed: 31862961
Cell. 1997 Oct 3;91(1):47-57
pubmed: 9335334
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
J Exp Med. 2015 Oct 19;212(11):1833-50
pubmed: 26438359
EMBO J. 2012 May 2;31(9):2076-89
pubmed: 22415365
Drug Discov Today Technol. 2019 Apr;31:15-27
pubmed: 31200855
EMBO J. 2017 Dec 15;36(24):3573-3599
pubmed: 29217591
Cell. 1997 Oct 3;91(1):35-45
pubmed: 9335333
Oncotarget. 2017 Jun 6;8(23):37619-37632
pubmed: 28430577
Nat Genet. 2013 Dec;45(12):1464-9
pubmed: 24121791
Nat Protoc. 2019 Mar;14(3):756-780
pubmed: 30710114
Nat Biotechnol. 2014 Dec;32(12):1262-7
pubmed: 25184501
J Cell Biol. 2000 Nov 13;151(4):749-62
pubmed: 11076961
Cell Stem Cell. 2015 Dec 3;17(6):675-688
pubmed: 26607380
ACS Chem Biol. 2015 Aug 21;10(8):1770-7
pubmed: 26035625
Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):32-41
pubmed: 17164524
Blood. 2014 Feb 6;123(6):914-20
pubmed: 24335498
Plant Cell Physiol. 2012 Jun;53(6):965-75
pubmed: 22433459
J Clin Invest. 2018 Jul 2;128(7):2951-2965
pubmed: 29649003
J Cell Biol. 2000 Aug 7;150(3):405-16
pubmed: 10931856
J Cell Biol. 2009 Oct 19;187(2):165-73
pubmed: 19822671
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Cancer Res. 2019 Sep 15;79(18):4744-4753
pubmed: 31311809
Nat Struct Mol Biol. 2014 Oct;21(10):864-70
pubmed: 25173175
Cold Spring Harb Perspect Med. 2016 Dec 1;6(12):
pubmed: 27742736
Acta Crystallogr D Struct Biol. 2018 Feb 1;74(Pt 2):85-97
pubmed: 29533234
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Cell Chem Biol. 2018 Jan 18;25(1):78-87.e5
pubmed: 29129718
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734

Auteurs

Petra van der Lelij (P)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
ORCID: 0000-0002-7461-9645

Joseph A Newman (JA)

Structural Genomics Consortium, University of Oxford, Oxford, UK.

Simone Lieb (S)

Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria.

Julian Jude (J)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Vittorio Katis (V)

Structural Genomics Consortium, University of Oxford, Oxford, UK.

Thomas Hoffmann (T)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Matthias Hinterndorfer (M)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Gerd Bader (G)

Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria.

Norbert Kraut (N)

Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria.

Mark A Pearson (MA)

Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria.

Jan-Michael Peters (JM)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Medical University of Vienna, VBC, Vienna, Austria.

Johannes Zuber (J)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria johannes.zuber@imp.ac.at.
Medical University of Vienna, VBC, Vienna, Austria.

Opher Gileadi (O)

Structural Genomics Consortium, University of Oxford, Oxford, UK opher.gileadi@sgc.ox.ac.uk.

Mark Petronczki (M)

Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria mark_paul.petronczki@boehringer-ingelheim.com.
ORCID: 0000-0003-0139-5692

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Systèmes CRISPR-Cas › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cycle cellulaire › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines chromosomiques nonhistones › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Phénomènes physiologiques › Constitution physique › Prédisposition aux maladies › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Ciblage de gène › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Épidémiologie moléculaire › Étude d'association pangénomique › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles moléculaires › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Tumeurs › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Métabolisme › Protéolyse › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › STAG1 vulnerabilities for exploiting cohesin...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutations synthétiques létales › STAG1 vulnerabilities for exploiting cohesin...